Publication:
Finasteride and its potential for the treatment of female pattern hair loss: Evidence to date

dc.contributor.authorWimolsiri Iamsumangen_US
dc.contributor.authorKanchana Leerunyakulen_US
dc.contributor.authorPoonkiat Suchonwaniten_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2020-03-26T05:12:57Z
dc.date.available2020-03-26T05:12:57Z
dc.date.issued2020-01-01en_US
dc.description.abstract© 2020 Iamsumang et al. The currently approved treatment for female pattern hair loss (FPHL) includes topical minoxidil administration; however, this treatment fails to achieve hair regrowth in some patients. Finasteride, a selective 5α-reductase inhibitor (5-ARI), may be considered as an alternative treatment. However, because of its potential teratogenic effects, clinical studies and use of finasteride for FPHL are limited. In this review, we aim to summarize the literature regarding the pharmacology, clinical efficacy, and adverse effects of oral finasteride for the treatment of FPHL and to provide novel therapeutic options including topical finasteride and dutasteride, a new generation 5-ARI, for the treatment of FPHL.en_US
dc.identifier.citationDrug Design, Development and Therapy. Vol.14, (2020), 951-959en_US
dc.identifier.doi10.2147/DDDT.S240615en_US
dc.identifier.issn11778881en_US
dc.identifier.other2-s2.0-85081032303en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/53907
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85081032303&origin=inwarden_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleFinasteride and its potential for the treatment of female pattern hair loss: Evidence to dateen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85081032303&origin=inwarden_US

Files

Collections